KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Net (2016 - 2024)

CRISPR Therapeutics AG's Receivables - Net history spans 10 years, with the latest figure at $25.0 million for Q4 2024.

  • For Q4 2024, Receivables - Net fell 87.5% year-over-year to $25.0 million; the TTM value through Dec 2024 reached $25.0 million, down 87.5%, while the annual FY2024 figure was $25.0 million, 87.5% down from the prior year.
  • Receivables - Net for Q4 2024 was $25.0 million at CRISPR Therapeutics AG, down from $200.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $200.0 million in Q4 2023 and bottomed at $33000.0 in Q2 2020.
  • The 5-year median for Receivables - Net is $150000.0 (2021), against an average of $23.0 million.
  • The largest annual shift saw Receivables - Net crashed 99.4% in 2021 before it surged 105960.61% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $144000.0 in 2020, then soared by 111.81% to $305000.0 in 2021, then plummeted by 83.93% to $49000.0 in 2022, then surged by 408063.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024.
  • Per Business Quant, the three most recent readings for CRSP's Receivables - Net are $25.0 million (Q4 2024), $200.0 million (Q4 2023), and $70.0 million (Q2 2023).